• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Malaysia Reaffirms Full Regulatory Compliance and Export-Only Manufacturing Operations

    6/9/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    LOS ANGELES, June 9, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that its Malaysian subsidiary, Ispire Malaysia Sdn Bhd ("Ispire Malaysia"), reaffirmed its strict compliance with all applicable Malaysian laws and regulations. This clarification follows recent media reports and public interest concerning the Company's manufacturing activities in Malaysia.

    Ispire Malaysia confirms that all manufacturing activities at its facility in Johor are exclusively for export purposes and do not involve the production or distribution of any nicotine- or cannabis-containing liquids or gels within Malaysia and for export.

    "Ispire Malaysia operates under stringent procedures to ensure all manufacturing is 100% export-oriented," said Michael Wang, Co-CEO of Ispire Technology Inc. "We believe our operations fully comply with Malaysian law, and we are committed to transparency and regulatory cooperation at both federal and state levels."

    Key Clarifications:

    • No Local Distribution: All products manufactured in Malaysia are not sold, distributed, or marketed in the Malaysian market.
    • No Nicotine or Cannabis Content: The facility produces semi-finished vaporizer hardware only, with no liquids or gels involved at any point in production.
    • No Medical Devices Manufactured: While the facility is capable of producing certified components, no medical devices are currently manufactured. Any future activity in this sector would follow a comprehensive regulatory review.
    • Advanced Safety Features: Ispire products will integrate blockchain-based age-gating and geo-fencing technology, ensuring use is restricted to adults and compliant areas. The company's patented technology has been submitted for review by the U.S. Food and Drug Administration.

    The Company also noted that recent commentary referencing cannabis-related products was based on marketing materials related to Ispire's U.S. operations, which operate in jurisdictions where such products are legal. These materials do not reflect the nature of the Company's business conducted in Malaysia.

    With an investment target exceeding USD 50 million, Ispire Malaysia has positioned itself as a premier manufacturing hub in Southeast Asia, supporting job creation and technological innovation aligned with Malaysia's industrial development goals.

    "We remain committed to upholding the highest standards of compliance, safety, and corporate responsibility," said Wang.

    For further information, please visit www.ispiretechnology.com.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company meeting its investment target in Malaysia as currently planned, to a lesser degree, or at all; the Company's continued compliance with applicable laws and regulations in the jurisdictions in which it operates; the approval or rejection of any PMTA submitted by the Company; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals regarding age-gating technology, or otherwise, as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's business strategies; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2024 and any subsequent filings which Ispire makes with the SEC, including the Ispire's Quarterly Report on Form 10-Q for the period ended March 31, 2025. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

    IR Contacts:

    For more information, kindly contact:

    Investor Relations

    Sherry Zheng

    718.213.7386

    [email protected]



    KCSA Strategic Communications

    Phil Carlson

    212.896.1233

    [email protected]



    PR Contact:

    Ellen Mellody

    570.209.2947

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/ispire-malaysia-reaffirms-full-regulatory-compliance-and-export-only-manufacturing-operations-302476734.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ispire Malaysia Reaffirms Full Regulatory Compliance and Export-Only Manufacturing Operations

      LOS ANGELES, June 9, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that its Malaysian subsidiary, Ispire Malaysia Sdn Bhd ("Ispire Malaysia"), reaffirmed its strict compliance with all applicable Malaysian laws and regulations. This clarification follows recent media reports and public interest concerning the Company's manufacturing activities in Malaysia. Ispire Malaysia confirms that all manufacturing activities at its facility in Johor are exclusively for export purposes and do not involve the production or distribution of any nicotine- or cannabis-containing liquids or gels within

      6/9/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire to Participate in the Benzinga Cannabis Capital Conference in Chicago on Tuesday, June 10, 2025

      Conference Attendance Follows Historic, First-Ever FDA Acceptance Review of a Standalone, Blockchain-Enabled Age-Gating System LOS ANGELES, June 6, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that the Company will participate in the Benzinga Cannabis Capital Conference, taking place from June 10-11, 2025, at the Marriott Magnificent Mile in Chicago, Illinois. Dennis Lider, SVP of Cannabis, will join the panel titled "The Hidden Winners in Cannabis: Profitable Businesses Without the Red Tape" on Tuesday, June 10, 2025, from 11:00 am to 11:30 am CDT on the Main Stage - Floor 5 (Chicag

      6/6/25 8:30:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire-Backed IKE Tech to Present 7th Annual Next Generation Nicotine Delivery USA Conference

      Conference Attendance Follows Groundbreaking FDA PMTA Filing for Blockchain-Powered Age-Gating System LOS ANGELES, June 3, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech"), a joint venture that includes Ispire as a founding partner, will showcase their technology at the 7th Annual Next Generation Nicotine Delivery USA at the Hyatt Regency in Miami from June 4-5th. This event convenes key business leaders from the FDA, the ENDS (Electronic Nicotine Delivery Systems) sector, and the tobacco industry across the U.S. market to explore strategies for legal compli

      6/3/25 8:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CLO and Secretary Pryzbyla Steven P. sold $1,785 worth of shares (500 units at $3.57), decreasing direct ownership by 0.12% to 416,710 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/19/25 4:30:15 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • CLO and Secretary Pryzbyla Steven P. sold $24,982 worth of shares (6,200 units at $4.03), decreasing direct ownership by 1% to 417,210 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      3/14/25 4:30:05 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Cox Brent was granted 8,077 shares, increasing direct ownership by 63% to 20,998 units (SEC Form 4)

      4 - Ispire Technology Inc. (0001948455) (Issuer)

      1/10/25 6:05:19 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Financials

    Live finance-specific insights

    See more
    • Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

      Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial PositionPost-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKELaunched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety  LOS ANGELES, May 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025. Fiscal Third Quarter 2025 Financial Results Revenue of $26.2 million versus $30.0 mil

      5/12/25 7:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technologies Inc. Schedules Fiscal Third Quarter 2025 Earnings Conference Call

      LOS ANGELAS, May 7, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00am ET on Monday, May 12, 2025, to discuss the Company's financial results for the fiscal third quarter ended March 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Monday, May 12, 2025Time: 8:00am ETDial-In Numbers: North America 888-880-3330 or International +1 646-357-8766This conference call will be webcast live and can be accessed by all

      5/7/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. to Participate in Webull Corporate Webinar Series on February 18, 2025

      LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Michael Wang, Co-Chief Executive Officer, will present at the Webull Consumer Webinar Series: Consumer, on February 18, 2025. Conference Details: Webull Corporate Webinar Series - ConsumerDate/Time: Tuesday, February 18th at approximately 3:00 p.m. ETPresenter: Michael Wang, Co-CEORegistration Link: HERERecent Highlights: 2/10/25: Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025 1/22/25: Ispire Technology Inc. Announces Stock Repurchase Program 1/15/25: Ispi

      2/12/25 8:00:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • ROTH MKM initiated coverage on Ispire Technology with a new price target

      ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

      5/20/24 7:18:59 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Ispire Technology Inc.

      SC 13G - Ispire Technology Inc. (0001948455) (Subject)

      7/12/24 5:00:02 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

      Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

      5/15/25 4:30:00 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. Announces Key Leadership Appointments

      LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ:ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today the appointment of Michael Wang as its Co-Chief Executive Officer.  Mr. Wang previously served as Chief Financial Officer. Concurrently, Daniel J. Machock was appointed as the new Chief Financial Officer. Mr. Wang has assumed the role of Co-Chief Executive Officer alongside Tuanfang Liu, as Co-Chief Executive Officer. This strengthened leadership structure is designed to refine Ispire's strategic direction and spearhead the Company's future growth. Ispire's decision

      8/14/23 8:35:00 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care

    $ISPR
    SEC Filings

    See more
    • Ispire Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/23/25 4:30:34 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/15/25 4:30:11 PM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ispire Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ispire Technology Inc. (0001948455) (Filer)

      5/12/25 7:00:13 AM ET
      $ISPR
      Medicinal Chemicals and Botanical Products
      Health Care